Psychometric Characteristics of the Persian Version of the Opiate Dosage Adequacy Scale (ODAS)
暂无分享,去创建一个
M. Zarrindast | E. Razaghi | N. Vousooghi | A. Torkaman-Boutorabi | Abdollah Golnezhad | Sara Yadollahi | Parviz Dousti Kataj
[1] K. Wenzel,et al. Sex-based differences in psychiatric symptoms and opioid abstinence during buprenorphine/naloxone treatment in adolescents with opioid use disorders. , 2021, Journal of substance abuse treatment.
[2] F. Altice,et al. The Real-World Impact of Dosing of Methadone and Buprenorphine on Retention on Opioid Agonist Therapies in Ukraine. , 2020, Addiction.
[3] J. Bruneau,et al. The authors respond to “Opioid agonist dosage adequacy from clinical and patient perspectives: further considerations” , 2019, Canadian Medical Association Journal.
[4] J. Trujols,et al. Opioid agonist dosage adequacy from clinical and patient perspectives: further considerations , 2019, Canadian Medical Association Journal.
[5] Nanor Minoyan,et al. Opioid agonist treatment dosage and patient-perceived dosage adequacy, and risk of hepatitis C infection among people who inject drugs , 2019, Canadian Medical Association Journal.
[6] F. González-Saiz,et al. Evidence of validity and reliability of the Opiate Dosage Adequacy Scale (ODAS) in a sample of heroin addicted patients in buprenorphine/naloxone maintenance treatment. , 2018, Drug and alcohol dependence.
[7] I. Ojanperä,et al. Polydrug abuse among opioid maintenance treatment patients is related to inadequate dose of maintenance treatment medicine , 2017, BMC Psychiatry.
[8] S. Durán-Sindreu,et al. Patient perception of methadone dose adequacy in methadone maintenance treatment: The role of perceived participation in dosage decisions. , 2017, Patient education and counseling.
[9] A. Rahimi-Movaghar,et al. Epidemiology of illicit drug use disorders in Iran: prevalence, correlates, comorbidity and service utilization results from the Iranian Mental Health Survey. , 2016, Addiction.
[10] J. Trujols,et al. Methadone maintenance treatment: the need to distinguish between holding dose, dose adequacy, satisfaction with methadone as a medication, and satisfaction with treatment. , 2010, Journal of clinical psychopharmacology.
[11] Arrastus Attarad,et al. Correlates of injection use of synthetic drugs among drug users in Pakistan: a case controlled study. , 2006, JPMA. The Journal of the Pakistan Medical Association.
[12] K. Humphreys,et al. Determining Effective Methadone Doses for Individual Opioid-Dependent Patients , 2006, PLoS medicine.
[13] W. Ling,et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. , 2003, The New England journal of medicine.
[14] H. W. Clark,et al. Office-based practice and opioid-use disorders. , 2003, The New England journal of medicine.
[15] J. White,et al. Patterns of symptom complaints in methadone maintenance patients. , 1997, Addiction.
[16] G. Woody,et al. The Effects of Psychosocial Services in Substance Abuse Treatment , 1993, JAMA.
[17] W. S. Condelli. Strategies for increasing retention in methadone programs. , 1993, Journal of psychoactive drugs.
[18] D. Metzger,et al. The Fifth Edition of the Addiction Severity Index. , 1992, Journal of substance abuse treatment.
[19] W K Bickel,et al. Buprenorphine: dose-related blockade of opioid challenge effects in opioid dependent humans. , 1988, The Journal of pharmacology and experimental therapeutics.
[20] H. Kaiser. A second generation little jiffy , 1970 .
[21] Jacob Cohen. A Coefficient of Agreement for Nominal Scales , 1960 .
[22] M. Krausz,et al. HEROIN ADDICTION AND RELATED CLINICAL PROBLEMS , 2002 .
[23] D. Cicchetti. Guidelines, Criteria, and Rules of Thumb for Evaluating Normed and Standardized Assessment Instruments in Psychology. , 1994 .
[24] D. Kleinbaum,et al. Clinic policy and retention in methadone maintenance. , 1993, The International journal of the addictions.
[25] G. Dunteman,et al. Exposure to methadone programs and heroin use. , 1993, The American journal of drug and alcohol abuse.